We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Bla6.0
B. lactis (BB-12 / HN019) Research
Mostly mechanism / observational
30 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most B. lactis (BB-12 / HN019) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2000–2026 with a typical study size of 80 participants.
Based on 30 studies · 4 meta-analyses · 17 RCTs · 3,098 total participants
Confidence
High confidence
By outcome
Digestive symptoms & gut microbiotaFaster gut transit (hours, measurable radiographically) and a small increase in stool frequency in people with low baseline frequency — the cited sources report an odds ratio for responder status and a significant effect on average defecation frequency, not a per-week figure, and the B. lactis-only pooled estimate was non-significant (WMD 1.34, 95% CI -0.27 to 2.94). No effect on bloating or abdominal pain · 2 weeks
Mostly mechanism / observational13 studies
Gut transit & bowel regularityFaster gut transit (hours, measurable radiographically) and a small increase in stool frequency in people with low baseline frequency — the cited sources report an odds ratio for responder status and a significant effect on average defecation frequency, not a per-week figure, and the B. lactis-only pooled estimate was non-significant (WMD 1.34, 95% CI -0.27 to 2.94). No effect on bloating or abdominal pain · 2 weeks
Mostly mechanism / observational12 studies
ConstipationFaster gut transit (hours, measurable radiographically) and a small increase in stool frequency in people with low baseline frequency — the cited sources report an odds ratio for responder status and a significant effect on average defecation frequency, not a per-week figure, and the B. lactis-only pooled estimate was non-significant (WMD 1.34, 95% CI -0.27 to 2.94). No effect on bloating or abdominal pain · 2 weeks
Mostly mechanism / observational6 studies
Immune functionEnhanced immune cell markers in the elderly, but these are laboratory biomarkers with no trial showing fewer actual infections · 3-6 weeks
Mostly mechanism / observational6 studies
Diarrhoea & enteric infection
Mostly mechanism / observational5 studies
Safety profile
Mostly mechanism / observational4 studies
Inflammation
Too few graded studies1 study
Active research area
17 studies in the last 5 years · Latest meta-analysis: 2022
200020132026
1RCTn=229 · medium study2024
In plain English: The largest and best-controlled trial of this strain for constipation was null, and the authors explicitly stated it did not confirm earlier positive results.
Cheng J et al. · JAMA Netw Open (2024)
Primary outcome (change in complete spontaneous bowel movements per week): +0.80 with HN019 vs +0.66 placebo — no difference
Triple-blind across 5 hospitals, 8 weeks, Rome III functional constipation
Dose 7.0 billion CFU/day falling to 4.69 billion at end of study
In plain English: The largest trial of this strain missed one co-primary endpoint and its pre-specified responder threshold, though average defecation frequency did exceed placebo.
Eskesen D et al. · Br J Nutr (2015)
Co-primary GI well-being endpoint (global relief of abdominal discomfort): not significant
Co-primary responder analysis: OR 1.31 (95% CI 0.98-1.75, p=0.071) — missed significance
A stricter responder definition did reach significance: OR 1.55 (95% CI 1.22-1.96, p=0.0003)
Agustina R, Ekawidyani KR, Mutiyani M, Prafiantini E, Nindya TS, Damayanti W, Rejeki PS, Djuari L, Huriyati E, Bines JE, Juffrie M. · BMJ open (2025)
The secondary outcomes will include changes in secretory IgA specific to SARS-CoV-2 titre concentrations, monoclonal antibodies against SARS-CoV-2 spike protein, gut microbiota diversity and the score of Healthy Eating Index 2015.
Ethics and dissemination The study protocol was approved by the Ethics Committee of the Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo Hospital (KET 763/UN2.F1/ETIK/PPM.00.02/2022: 1 August 2022).
The study results will be disseminated in open-access international journals, scientific meetings and conferences with stakeholders.
In plain English: Probiotics supplementation with Ritalin may have some beneficial effects among ADHD children and adolescents, such as improving auditory response control and total score of CPRS.
Sangsefidi ZS et al. · Nutritional neuroscience (2025)
This study showed a significant decrease in the CPRS total score after 4 weeks of intervention in the probiotic group (baseline: 43.96 ± 21.52; fourth week: 37.22 ± 23.01; p = 0.01).
Moreover, at the end of the study, a significant increase was observed in score of auditory response control in the probiotic versus the placebo group (probiotic: 91.55 ± 16.69; placebo: 80.55 ± 17.43; p = 0.02).
Probiotics supplementation with Ritalin may have some beneficial effects among ADHD children and adolescents, such as improving auditory response control and total score of CPRS.
Ye M, Xu X, Huang W, Du X, Liu Y, Yang G. · Frontiers in nutrition (2026)
For AOM incidence, only CBA-L74 (OR = 0.27, 95% CI: 0.11-0.68; SUCRA = 89.3%) and SS-K12 (OR = 0.44, 95% CI: 0.20-0.94; SUCRA = 71.8%) achieved statistically significant reductions vs. placebo.
Sensitivity analyses excluding two high risk-of-bias trials showed that SS-K12's effect was substantially attenuated and lost significance, whereas CBA-L74 remained robustly effective (OR = 0.28, 95% CI: 0.14-0.56).
For antibiotic prescription rates, Multi-strain (OR = 0.45; SUCRA = 87.1%) and LGG (OR = 0.69; SUCRA = 65.3%) demonstrated significant reductions; both were superior to SS-K12 in direct pairwise comparisons.
Alikamali M, Mohammad-Alizadeh-Charandabi S, Mirghafourvand M, Gharehbaghi MM, Homayouni-Rad A, Fardiazar Z, Shahnazi M. · BMJ open (2024)
Modified intention-to-treat analyses will be employed for the primary and secondary outcomes, excluding participants lost to follow-up from all postintervention assessments.
Ethics and dissemination This study protocol has been approved by the Medical University of Tabriz Ethics Committee (IR.TBZMED.REC.1401.735).
Findings will be disseminated through publication in a peer-reviewed journal and presentations at relevant conferences.
In plain English: Pooling 30 probiotic RCTs, Bifidobacterium lactis was one of the few organisms with a significant effect on stool frequency — directly contradicting an earlier meta-analysis.
van der Schoot A et al. · Clin Nutr (2022)
Response to probiotic treatment 369/647 (57%) vs 252/567 (44%) control — RR 1.28 (95% CI 1.07-1.52, p=0.007)
Probiotics increased stool frequency overall (SMD 0.71, 95% CI 0.37-1.04, p<0.00001), with Bifidobacterium lactis specifically showing a significant effect
Probiotic mixtures, Bacillus coagulans Unique IS2 and Lactobacillus casei Shirota did NOT show a significant frequency effect
In plain English: Probiotics overall shortened whole-gut transit by nearly 14 hours, but B. lactis alone did not significantly increase stool frequency.
Zhang C et al. · Clin Nutr (2020)
Whole gut transit time reduced by 13.75 hours overall (95% CI -21.93 to -5.56)
B. lactis alone did NOT significantly raise stool frequency (WMD 1.34, 95% CI -0.27 to 2.94)
Multispecies products outperformed single strains on several endpoints
In plain English: Pooled species-level data show more frequent bowel movements and faster transit in short courses, but no improvement in abdominal pain or bloating.
Araújo MM et al. · Nutr Rev (2022)
Defecation frequency: SMD 0.26 (95% CI 0.13-0.39) in healthy adults
Colonic transit time reduced only in the 14-days-or-less subgroup: SMD -0.34 (95% CI -0.62 to -0.07)
Stool consistency improved (SMD 0.76) but only in individuals WITHOUT GI symptoms
In plain English: Using radiographic markers rather than questionnaires, whole-gut transit time fell from 49 to 21 hours on the higher dose in 14 days.
Waller PA et al. · Scand J Gastroenterol (2011)
Whole-gut transit fell 49 to 21 hours on high dose (p<0.001) and 60 to 41 hours on low dose (p=0.01); placebo unchanged
Doses were 17.2 billion CFU/day (high) and 1.8 billion CFU/day (low) over 14 days
8 of 9 functional GI symptoms decreased in frequency on high dose, 7 of 9 on low dose, 2 of 9 on placebo
In plain English: 624 children aged 1-4 were followed for a year on prebiotic-plus-HN019 milk; the diarrhoea primary outcome was null, though respiratory and febrile morbidity fell.
Sazawal S et al. · PLoS One (2010)
PRIMARY DIARRHOEA OUTCOME NULL: 6% reduction (95% CI -1 to 12%, p=0.08)
Dysentery episodes reduced 21% (95% CI 0 to 38%, p=0.05); pneumonia 24% (95% CI 0 to 42%, p=0.05); severe acute lower respiratory infection 35% (95% CI 0 to 58%, p=0.05)
Days with severe illness reduced 16% (95% CI 5 to 26%, p=0.004) and days with high fever 5% (95% CI 0 to 10%, p=0.05)
In plain English: The significance of our study is in simultaneously assessing the effect of BB-12, alone and in different delivery vehicles, on the gut transit time, fecal short-chain fatty acids, and the composition of the gut microbiota of the study cohort.
Ba Z et al. · mSphere (2021)
Participants had significantly higher percentage of Streptococcus after consuming YS versus CAP (P = 0.01).
Bifidobacterium-specific terminal restriction fragment length polymorphism analysis revealed a significantly higher percentage of B. animalis after consuming PRE and POST compared to baseline, YS, CAP, and final washout (P < 0.0001).
In addition to fermented dairy products, many new probiotic-containing alternatives such as probiotic-containing juice, probiotic-containing chocolate, and capsules have been developed.
In plain English: To fully realize their therapeutic promise, future research must pursue large-scale, head-to-head clinical trials, integrate multiomics and precision-design approaches, and establish standardized frameworks for safety monitoring and personalized formulation.
Vergara Nieto ÁA, Diaz AH, Millán MH, Sagredo D, Gacitua JA. · The Journal of nutritional biochemistry (2026)
Probiotics exert strain-specific, multimechanistic benefits on gut barrier integrity, neuroendocrine signaling, and cardiometabolic regulation.
To fully realize their therapeutic promise, future research must pursue large-scale, head-to-head clinical trials, integrate multiomics and precision-design approaches, and establish standardized frameworks for safety monitoring and personalized formulation.
In plain English: Clinical studies have demonstrated the safety and beneficial effects of BB-12 in infants and children across multiple disorders and highlight the need for improved clinical and regulatory guidelines.
Bueno CPAR, Domínguez AC, Guyonnet D, Pouteau E. · Frontiers in microbiology (2026)
Bifidobacteria-dominance in infancy is considered protective as they not only display both anti-inflammatory and immunomodulatory effects but also foster the establishment of other beneficial species via cross-feeding interactions.
As predominance of bifidobacteria is considered the marker of a healthy breastfed infant, the use of bifidobacteria-based probiotics for the prevention of gut dysbiosis and related conditions has been investigated.
Clinical studies have demonstrated the safety and beneficial effects of BB-12 in infants and children across multiple disorders and highlight the need for improved clinical and regulatory guidelines.
In plain English: Collectively, the well documented clinical efficacies demonstrated by BB-12 are most likely not through one single mechanism, but through the collective direct and indirect effects the strain has on both its environment and the host.
Collins FWJ, Vera-Jiménez NI, Wellejus A. · Frontiers in microbiology (2025)
The BB-12 Bifidobacterium animalis subsp. lactis strain is one of the most documented probiotic strains on the market and has been shown to be effective in alleviating symptoms of a low defecation frequency and infant colic, among others.
In this review, we examine the wide range of preclinical and clinical data available for the strain, to help elucidate some of its potential mechanisms of action.
We describe the defence mechanisms developed by the strain to ensure gastrointestinal survival and transit, as well as the current knowledge on how BB-12 interacts with the host epithelial lining and cells of the immune system and the relationship between the strain and the gut microbiota.
In plain English: From our data, synbiotic supplementation showed a subtle benefit in gut functioning in apparently healthy community-dwelling elders.
Valentini Neto J et al. · Arquivos de gastroenterologia (2020)
From our data, synbiotic supplementation showed a subtle benefit in gut functioning in apparently healthy community-dwelling elders.
Our findings can suggest that the benefits in healthy individuals were less expressive than the ones presented in studies with individuals previously diagnosed as dysbiosis.
Future studies, comparing elders with and without gut dysbiosis can confirm our findings.